Kiniksa CMO gets 26,750-share option, 6,700 RSUs

KNSA’s chief medical officer received new RSU and option grants while prior RSUs vested into shares, with a portion of shares withheld for taxes or exercise costs.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) reported that its chief medical officer, John F. Paolini, received equity awards and had previously granted RSUs vest on September 1, 2026. He was granted 6,700 Restricted Share Units, each representing one Class A Ordinary Share, vesting in four annual installments starting September 1, 2026, and a share option for 26,750 Class A Ordinary Shares at an exercise price of $79.28 per share, expiring August 31, 2036, with vesting beginning September 1, 2026. On the same date, RSUs from earlier grants dated September 1, 2022, 2023, 2024, and 2025 vested, resulting in the exercise or conversion of 8,328 RSUs into Class A Ordinary Shares. Of the shares issued upon these vestings, 4,029 Class A Ordinary Shares were delivered or withheld at $79.28 per share for payment of exercise price or tax liability. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

8,328 shares exercised/converted

Exercise 11 txns

Insider Paolini John F.

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Unit F1, F2	6,700	$0.00	$0.00
Grant/Award	Share Option F3	26,750	$0.00	$0.00
Exercise	Restricted Share Unit F1, F4	2,457	$0.00	$0.00
Exercise	Restricted Share Unit F1, F5, F2	1,750	$0.00	$0.00
Exercise	Restricted Share Unit F1, F6	1,624	$0.00	$0.00
Exercise	Restricted Share Unit F1, F7	2,497	$0.00	$0.00
Exercise	Class A Ordinary Share F1	2,497	--	--
Exercise	Class A Ordinary Share F1	1,624	--	--
Exercise	Class A Ordinary Share F1	1,750	--	--
Exercise	Class A Ordinary Share F1	2,457	--	--
Exercise Price or Tax Liability	Class A Ordinary Share	4,029	$79.28	$319K

Holdings After Transaction: Restricted Share Unit — 19,195 contracts (Direct); Share Option — 26,750 contracts (Direct); Class A Ordinary Share — 69,922 shares (Direct)

Footnotes (7)

1. F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
2. F2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
3. F3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
4. F4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
5. F5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
6. F6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
7. F7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Key Figures

RSUs granted: 6,700 units Share options granted: 26,750 shares Option exercise price: $79.28 per share +3 more

6 metrics

RSUs granted 6,700 units Restricted Share Units granted to John F. Paolini on September 1, 2026

Share options granted 26,750 shares Share option for Class A Ordinary Shares granted on September 1, 2026

Option exercise price $79.28 per share Exercise price of the 26,750-share option granted to John F. Paolini

Option expiration August 31, 2036 Expiration date of the 26,750-share option award

RSUs exercised or converted 8,328 units Total RSUs exercised or converted into shares on September 1, 2026

Shares withheld for exercise price or tax 4,029 shares Shares delivered or withheld at $79.28 per share for exercise price or tax liability

Key Terms

Restricted Share Unit, Share Option, vesting commencement date, exercise price or tax liability

4 terms

Restricted Share Unit financial

"Each Restricted Share Unit (RSU) represents a contingent right to receive"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Share Option financial

"The option vests and becomes exercisable as to 25% of the total grant"

vesting commencement date financial

"The vesting commencement date is September 1, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercise price or tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

What equity awards did KNSA grant to its CMO John F. Paolini on September 1, 2026?

On September 1, 2026, John F. Paolini was granted 6,700 Restricted Share Units and a share option for 26,750 Class A Ordinary Shares with an exercise price of $79.28 per share, subject to multi‑year vesting schedules starting September 1, 2026.

How do the new RSUs granted to KNSA’s CMO vest?

The 6,700 RSUs granted to John F. Paolini vest over four years, with 25% vesting on each yearly anniversary of the grant date, beginning on September 1, 2026.

What are the key terms of the new share option granted by KNSA (KNSA) to its CMO?

The share option covers 26,750 Class A Ordinary Shares at an exercise price of $79.28 per share, vests as to 25% on the first anniversary of the vesting commencement date September 1, 2026, then in 36 equal monthly installments, and expires on August 31, 2036.

How many RSUs for KNSA’s CMO vested and were converted into shares on September 1, 2026?

On September 1, 2026, a total of 8,328 RSUs from prior grants dated September 1, 2022, 2023, 2024, and 2025 were exercised or converted into 8,328 Class A Ordinary Shares.

How many KNSA shares were withheld or delivered to cover tax or exercise costs?

On September 1, 2026, 4,029 Class A Ordinary Shares were delivered or withheld at $79.28 per share for payment of exercise price or tax liability related to equity awards.

Were KNSA CMO John F. Paolini’s transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:51 PM Accepted by SEC EDGAR 09/03/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/01/2026		M		2,497	A	(1)	68,120	D
Class A Ordinary Share	09/01/2026		M		1,624	A	(1)	69,744	D
Class A Ordinary Share	09/01/2026		M		1,750	A	(1)	71,494	D
Class A Ordinary Share	09/01/2026		M		2,457	A	(1)	73,951	D
Class A Ordinary Share	09/01/2026		F		4,029	D	$79.28	69,922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	09/01/2026		A		6,700		(2)	(2)	Class A Ordinary Share	6,700	$0	6,700	D
Share Option	$79.28	09/01/2026		A		26,750		(3)	08/31/2036	Class A Ordinary Share	26,750	$0	26,750	D
Restricted Share Unit	(1)	09/01/2026		M			2,457	(4)	(4)	Class A Ordinary Share	2,457	$0	7,371	D
Restricted Share Unit	(1)	09/01/2026		M			1,750	(5)	(2)	Class A Ordinary Share	1,750	$0	3,500	D
Restricted Share Unit	(1)	09/01/2026		M			1,624	(6)	(6)	Class A Ordinary Share	1,624	$0	1,624	D
Restricted Share Unit	(1)	09/01/2026		M			2,497	(7)	(7)	Class A Ordinary Share	2,497	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.

3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.

5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

	/s/ Douglas Barry, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)